Literature DB >> 22378379

Sildenafil treatment prevents glomerular hypertension and hyperfiltration in rats with renal ablation.

Edilia Tapia1, Laura G Sanchez-Lozada, Virgilia Soto, Andrés M Manrique, Karla M Ortiz-Vega, José Santamaría, Omar N Medina-Campos, Magdalena Cristóbal, Carmen Avila-Casado, José Pedraza-Chaverri, Bernardo Rodríguez-Iturbe, Martha Franco.   

Abstract

BACKGROUND: Sildenafil treatment ameliorates progressive renal injury resulting from extensive renal ablation; however, modifications induced by sildenafil in the glomerular hemodynamic pathophysiology of the remnant kidney have not been investigated. AIM: To determine the effects of sildenafil in the glomerular microcirculation and their relation to histological damage in the renal ablation model.
METHODS: Micropuncture studies were performed 60 days after 5/6 nephrectomy in rats that received no treatment, sildenafil (5 mg/kg/day) and reserpine, hydralazine and hydrochlorothiazide to maintain the blood pressure within normal levels. Sham-operated rats untreated and treated with sildenafil served as controls.
RESULTS: As expected, renal ablation induced systemic and glomerular hypertension, hyperfiltration, proteinuria, glomerulosclerosis and tubulointerstitial inflammatory damage in the remnant kidney. Sildenafil treatment prevented single-nephron hyperfiltration and hypertension, suppressed renal arteriolar remodeling, ameliorated systemic hypertension and proteinuria, increased urinary excretion of cGMP and NO(2)(-)/NO(3)(-), decreased oxidative stress and improved histological damage in the remnant kidney. Normalization blood pressure with reserpine, hydralazine and hydrochlorothiazide did not modify glomerular hemodynamics, proteinuria or histological changes induced by renal ablation.
CONCLUSIONS: Beneficial effects of sildenafil in the remnant kidney are associated with a reduction in the arteriolar remodeling, renal inflammatory changes and prevention of changes in the glomerular microcirculation.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378379     DOI: 10.1159/000334952

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  18 in total

1.  Salvianolic acid A attenuates kidney injury and inflammation by inhibiting NF-κB and p38 MAPK signaling pathways in 5/6 nephrectomized rats.

Authors:  Hong-Feng Zhang; Yan-Li Wang; Cheng Gao; Yan-Ting Gu; Jian Huang; Jin-Hui Wang; Jia-Hong Wang; Zhou Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-05-23       Impact factor: 6.150

2.  Tangeretin ameliorates renal failure via regulating oxidative stress, NF-κB-TNF-α/iNOS signalling and improves memory and cognitive deficits in 5/6 nephrectomized rats.

Authors:  Jing Wu; Yu-Mei Zhao; Zhi-Kuan Deng
Journal:  Inflammopharmacology       Date:  2017-09-04       Impact factor: 4.473

Review 3.  Reno-protective effects of Phosphodiesterase 5 inhibitors.

Authors:  Enis Rauf Coskuner; Burak Ozkan
Journal:  Clin Exp Nephrol       Date:  2021-03-22       Impact factor: 2.801

4.  Rutin ameliorates renal fibrosis and proteinuria in 5/6-nephrectomized rats by anti-oxidation and inhibiting activation of TGFβ1-smad signaling.

Authors:  Yu Han; Jin-Shan Lu; Yong Xu; Lei Zhang; Bao-Fa Hong
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.

Authors:  Kyle H Moore; John S Clemmer
Journal:  Am J Physiol Renal Physiol       Date:  2021-09-06

6.  Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis.

Authors:  Wenpeng Cui; Hasiyeti Maimaitiyiming; Xinyu Qi; Heather Norman; Qi Zhou; Xiaojun Wang; Jian Fu; Shuxia Wang
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 8.  Phosphodiesterase type 5 inhibitors and kidney disease.

Authors:  Baris Afsar; Alberto Ortiz; Adrian Covic; Abduzhappar Gaipov; Tarik Esen; David Goldsmith; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-08-05       Impact factor: 2.370

9.  Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.

Authors:  Wim Scheele; Susan Diamond; Jeremy Gale; Valerie Clerin; Nihad Tamimi; Vu Le; Rosalind Walley; Fernando Grover-Páez; Christelle Perros-Huguet; Timothy Rolph; Meguid El Nahas
Journal:  J Am Soc Nephrol       Date:  2016-04-25       Impact factor: 10.121

10.  Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats.

Authors:  Edilia Tapia; Virgilia Soto; Karla Mariana Ortiz-Vega; Guillermo Zarco-Márquez; Eduardo Molina-Jijón; Magdalena Cristóbal-García; José Santamaría; Wylly Ramsés García-Niño; Francisco Correa; Cecilia Zazueta; José Pedraza-Chaverri
Journal:  Oxid Med Cell Longev       Date:  2012-08-07       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.